Which has stronger earnings and valuation, IMVT or QURE?

uniQure has higher revenue and earnings than Immunovant. uniQure is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunovant N/A N/A -$505.61M -$2.78 N/A uniQure $16.10M 192.11 -$198.97M -$3.48 N/A

Is IMVT or QURE more profitable?

Immunovant has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Immunovant's return on equity of -65.66% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% uniQure -1,154.42% -145.81% -27.15%

Does the media refer more to IMVT or QURE?

In the previous week, uniQure had 60 more articles in the media than Immunovant. MarketBeat recorded 62 mentions for uniQure and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat uniQure's score of 0.50 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Is LEGN or QURE more profitable?

Legend Biotech has a net margin of -21.98% compared to uniQure's net margin of -1,154.42%. Legend Biotech's return on equity of -24.92% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% uniQure -1,154.42% -145.81% -27.15%

Does the media refer more to LEGN or QURE?

In the previous week, uniQure had 56 more articles in the media than Legend Biotech. MarketBeat recorded 62 mentions for uniQure and 6 mentions for Legend Biotech. uniQure's average media sentiment score of 0.50 beat Legend Biotech's score of 0.18 indicating that uniQure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, PTCT or QURE?

PTC Therapeutics has higher revenue and earnings than uniQure. PTC Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PTC Therapeutics $1.73B 3.94 $682.64M -$2.33 N/A uniQure $16.10M 192.11 -$198.97M -$3.48 N/A

Is PTCT or QURE more profitable?

PTC Therapeutics has a net margin of -22.58% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat PTC Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PTC Therapeutics -22.58% -362.45% -6.76% uniQure -1,154.42% -145.81% -27.15%

Does the media prefer PTCT or QURE?

In the previous week, uniQure had 49 more articles in the media than PTC Therapeutics. MarketBeat recorded 62 mentions for uniQure and 13 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.69 beat uniQure's score of 0.50 indicating that PTC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, QURE or MIRM?

Mirum Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 192.11 -$198.97M -$3.48 N/A Mirum Pharmaceuticals $521.31M 13.01 -$23.36M -$13.61 N/A

Does the media favor QURE or MIRM?

In the previous week, uniQure had 54 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat uniQure's score of 0.50 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor QURE or RYTM?

In the previous week, uniQure had 58 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.83 beat uniQure's score of 0.50 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 23 Very Positive mention(s) 9 Positive mention(s) 17 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

uniQure (QURE) Competitors

$49.04 +4.65 (+10.48%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$48.72 -0.31 (-0.64%)

As of 06/23/2026 07:55 PM Eastern

Compare

QURE vs. IMVT, LEGN, PTCT, MIRM, and RYTM

Should you buy uniQure stock or one of its competitors? MarketBeat compares uniQure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with uniQure include Immunovant (IMVT), Legend Biotech (LEGN), PTC Therapeutics (PTCT), Mirum Pharmaceuticals (MIRM), and Rhythm Pharmaceuticals (RYTM). These companies are all part of the "pharmaceutical products" industry.

How does uniQure compare to Immunovant?

Immunovant (NASDAQ:IMVT) and uniQure (NASDAQ:QURE) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Immunovant presently has a consensus target price of $37.33, suggesting a potential downside of 0.76%. uniQure has a consensus target price of $58.92, suggesting a potential upside of 20.14%. Given uniQure's stronger consensus rating and higher possible upside, analysts plainly believe uniQure is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, uniQure had 60 more articles in the media than Immunovant. MarketBeat recorded 62 mentions for uniQure and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.79 beat uniQure's score of 0.50 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has higher revenue and earnings than Immunovant. uniQure is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A

47.1% of Immunovant shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunovant has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Immunovant's return on equity of -65.66% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
uniQure	-1,154.42%	-145.81%	-27.15%

Summary

uniQure beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does uniQure compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and uniQure (NASDAQ:QURE) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Legend Biotech presently has a consensus target price of $60.23, suggesting a potential upside of 105.57%. uniQure has a consensus target price of $58.92, suggesting a potential upside of 20.14%. Given Legend Biotech's stronger consensus rating and higher possible upside, equities analysts plainly believe Legend Biotech is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

In the previous week, uniQure had 56 more articles in the media than Legend Biotech. MarketBeat recorded 62 mentions for uniQure and 6 mentions for Legend Biotech. uniQure's average media sentiment score of 0.50 beat Legend Biotech's score of 0.18 indicating that uniQure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 0.0% of Legend Biotech shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Legend Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

uniQure has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.14B	4.78	-$296.80M	-$0.68	N/A
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A

Legend Biotech has a net margin of -21.98% compared to uniQure's net margin of -1,154.42%. Legend Biotech's return on equity of -24.92% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
uniQure	-1,154.42%	-145.81%	-27.15%

Summary

uniQure beats Legend Biotech on 9 of the 16 factors compared between the two stocks.

How does uniQure compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and uniQure (NASDAQ:QURE) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

78.8% of uniQure shares are held by institutional investors. 5.5% of PTC Therapeutics shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PTC Therapeutics presently has a consensus target price of $91.36, suggesting a potential upside of 11.23%. uniQure has a consensus target price of $58.92, suggesting a potential upside of 20.14%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.71
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

PTC Therapeutics has higher revenue and earnings than uniQure. PTC Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$1.73B	3.94	$682.64M	-$2.33	N/A
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A

PTC Therapeutics has a net margin of -22.58% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
uniQure	-1,154.42%	-145.81%	-27.15%

PTC Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

In the previous week, uniQure had 49 more articles in the media than PTC Therapeutics. MarketBeat recorded 62 mentions for uniQure and 13 mentions for PTC Therapeutics. PTC Therapeutics' average media sentiment score of 0.69 beat uniQure's score of 0.50 indicating that PTC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

PTC Therapeutics beats uniQure on 9 of the 17 factors compared between the two stocks.

How does uniQure compare to Mirum Pharmaceuticals?

uniQure (NASDAQ:QURE) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 8.3% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

uniQure presently has a consensus target price of $58.92, suggesting a potential upside of 20.14%. Mirum Pharmaceuticals has a consensus target price of $139.80, suggesting a potential upside of 25.73%. Given Mirum Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Mirum Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Mirum Pharmaceuticals has a net margin of -140.24% compared to uniQure's net margin of -1,154.42%. Mirum Pharmaceuticals' return on equity of -11.28% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Mirum Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A
Mirum Pharmaceuticals	$521.31M	13.01	-$23.36M	-$13.61	N/A

In the previous week, uniQure had 54 more articles in the media than Mirum Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 8 mentions for Mirum Pharmaceuticals. Mirum Pharmaceuticals' average media sentiment score of 0.92 beat uniQure's score of 0.50 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

Summary

Mirum Pharmaceuticals beats uniQure on 12 of the 17 factors compared between the two stocks.

How does uniQure compare to Rhythm Pharmaceuticals?

uniQure (NASDAQ:QURE) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

Rhythm Pharmaceuticals has a net margin of -93.33% compared to uniQure's net margin of -1,154.42%. uniQure's return on equity of -145.81% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

uniQure presently has a consensus price target of $58.92, suggesting a potential upside of 20.14%. Rhythm Pharmaceuticals has a consensus price target of $133.13, suggesting a potential upside of 25.36%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, uniQure had 58 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 62 mentions for uniQure and 4 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.83 beat uniQure's score of 0.50 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	23 Very Positive mention(s)	9 Positive mention(s)	17 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

uniQure has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than uniQure. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	192.11	-$198.97M	-$3.48	N/A
Rhythm Pharmaceuticals	$189.76M	38.35	-$196.54M	-$3.13	N/A

Summary

Rhythm Pharmaceuticals beats uniQure on 11 of the 17 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.80B	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-14.09	19.75	24.92	23.98
Price / Sales	192.11	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	15.37	8.29	10.79	6.50
Net Income	-$198.97M	$23.85M	$3.56B	$336.88M
7 Day Performance	1.83%	2.87%	1.00%	-0.14%
1 Month Performance	102.73%	2.19%	0.42%	0.77%
1 Year Performance	244.87%	55.48%	29.70%	28.49%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	2.6904 of 5 stars	$49.04 +10.5%	$58.92 +20.1%	+251.5%	$2.80B	$16.10M	N/A	500	Trending News Insider Trade
IMVT Immunovant	1.7671 of 5 stars	$33.62 +2.3%	$37.33 +11.0%	+143.2%	$6.75B	N/A	N/A	120
LEGN Legend Biotech	4.4006 of 5 stars	$35.87 -1.1%	$60.23 +67.9%	-13.4%	$6.74B	$1.03B	N/A	2,965
PTCT PTC Therapeutics	2.5418 of 5 stars	$75.14 +0.6%	$91.36 +21.6%	+65.6%	$6.20B	$1.73B	N/A	1,410	News Coverage Insider Trade
MIRM Mirum Pharmaceuticals	4.1272 of 5 stars	$99.35 -0.2%	$138.36 +39.3%	+121.1%	$6.07B	$521.31M	N/A	140	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. IMVT, LEGN, PTCT, MIRM, and RYTM

How does uniQure compare to Immunovant?

Summary

How does uniQure compare to Legend Biotech?

Summary

How does uniQure compare to PTC Therapeutics?

Summary

How does uniQure compare to Mirum Pharmaceuticals?

Summary

How does uniQure compare to Rhythm Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. IMVT, LEGN, PTCT, MIRM, and RYTM

How does uniQure compare to Immunovant?

Do analysts rate IMVT or QURE?

Which has more risk and volatility, IMVT or QURE?

Does the media refer more to IMVT or QURE?

Which has stronger earnings and valuation, IMVT or QURE?

Do institutionals and insiders hold more shares of IMVT or QURE?

Is IMVT or QURE more profitable?

Summary

How does uniQure compare to Legend Biotech?

Do analysts rate LEGN or QURE?

Does the media refer more to LEGN or QURE?

Do institutionals and insiders hold more shares of LEGN or QURE?

Which has more risk and volatility, LEGN or QURE?

Which has stronger earnings and valuation, LEGN or QURE?

Is LEGN or QURE more profitable?

Summary

How does uniQure compare to PTC Therapeutics?

Do insiders & institutionals hold more shares of PTCT or QURE?

Do analysts recommend PTCT or QURE?

Which has higher earnings & valuation, PTCT or QURE?

Is PTCT or QURE more profitable?

Which has more volatility & risk, PTCT or QURE?

Does the media prefer PTCT or QURE?

Summary

How does uniQure compare to Mirum Pharmaceuticals?

Do insiders & institutionals have more ownership in QURE or MIRM?

Do analysts rate QURE or MIRM?

Is QURE or MIRM more profitable?

Which has higher valuation and earnings, QURE or MIRM?

Does the media favor QURE or MIRM?

Which has more risk and volatility, QURE or MIRM?

Summary

How does uniQure compare to Rhythm Pharmaceuticals?

Is QURE or RYTM more profitable?

Do analysts prefer QURE or RYTM?

Does the media favor QURE or RYTM?

Do institutionals & insiders have more ownership in QURE or RYTM?

Which has more volatility and risk, QURE or RYTM?

Which has preferable valuation and earnings, QURE or RYTM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools